Welcome to our dedicated page for CASTLE BIOSCIENCES SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CASTLE BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CASTLE BIOSCIENCES's regulatory disclosures and financial reporting.
Castle Biosciences (CSTL) reported insider transactions by President & CEO and Director Derek Maetzold. Under a Rule 10b5-1 plan adopted on May 8, 2025, he sold 6,458 shares on 11/04/2025 at a weighted-average price of $30.413, 237 shares on 11/04/2025 at $31.117, and 2,678 shares on 11/05/2025 at $31.851.
Following these sales, he held 53,615 shares directly. He also reports indirect holdings through family trusts, including 85,959 shares in DJM Grantor Retained Annuity Trust No. 5.
Castle Biosciences (CSTL) disclosed that its Chief Operating Officer reported an open-market sale of 12,678 shares of common stock on 10/31/2025 at a weighted-average price of $25.04, executed in multiple trades within a $25.00–$25.12 range. The sale was made pursuant to a Rule 10b5-1 plan adopted on March 6, 2025.
Following the transaction, the reporting person beneficially owns 27,569 shares directly and 100,937 shares indirectly through The Fritz Shorter Trust.
Castle Biosciences (CSTL): Form 4/A amendment reports that the Chief Operating Officer sold 18,007 shares of common stock on 08/27/2025 at a weighted-average price of $21.69, with trades executed between $21.24 and $21.94. The amendment clarifies the sale was made by the Fritz Shorter Trust, not directly by the executive.
Following the sale, holdings were 52,924 shares held directly and 100,937 shares held indirectly through the Trust. The filing also notes prior transfers to the Trust of 96,322 shares on March 19, 2025 and 22,622 shares on August 22, 2025.
Castle Biosciences, Inc. (CSTL) filed a Form S-8 to register 700,000 additional shares of common stock under its Castle Biosciences, Inc. 2022 Inducement Plan. The filing uses General Instruction E to register additional securities of the same class and incorporates prior S-8 filings by reference.
The company references its 2024 Form 10-K and 2025 quarterly and current reports for incorporation by reference, and lists standard exhibits including a legal opinion and auditor consent. Castle Biosciences identifies itself as an accelerated filer, and the registration statement is signed by President and CEO Derek J. Maetzold.
Castle Biosciences (CSTL) reported Q3 2025 results. Net revenues were $83.0 million versus $85.8 million a year ago, and the quarter showed a net loss of $0.5 million compared with net income of $2.3 million. For the nine months, net revenues reached $257.2 million, up from $245.8 million, while the company posted a net loss of $21.8 million versus income of $8.7 million last year.
Operating expenses rose on higher cost of sales and SG&A, and year‑to‑date amortization increased after the discontinuation of IDgenetix, which accelerated $20.1 million of expense. The balance sheet remained strong with cash and cash equivalents of $85.6 million and marketable investment securities of $202.0 million as of September 30, 2025. Year‑to‑date cash provided by operating activities was $37.4 million.
Dermatologic testing contributed $48.5 million and non‑dermatologic $34.5 million in Q3. The company closed an asset acquisition of Capsulomics (developed technology valued at $28.2 million) and entered a collaboration with SciBase. Long‑term debt stood at $10.0 million; the interest‑only period on the term loan was extended to December 1, 2026.
Castle Biosciences (CSTL) furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1. The company also made available an investor slide presentation as Exhibit 99.2.
The materials were furnished under Items 2.02 and 7.01 and are not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated into other filings except by specific reference.
Castle Biosciences (CSTL) CEO and President Derek Maetzold reported an open‑market sale of common stock. On 10/20/2025, he sold 1,339 shares at a weighted‑average price of $22.44, marked with transaction code S and made pursuant to a Rule 10b5‑1 plan adopted on May 8, 2025.
Following the transaction, his direct beneficial ownership stands at 62,988 shares. He also reports indirect holdings through various trusts, including 85,959 shares by DJM Grantor Retained Annuity Trust No. 5 and 52,923 shares by The Maetzold Descendants 2020 Trust. The sale price reflects multiple trades executed between $22.290 and $22.615, with the weighted‑average disclosed.
Dimensional Fund Advisors LP reported beneficial ownership of 1,474,089 shares of Castle Biosciences Inc common stock, representing 5.1% of the class. The filing states these shares are owned by investment funds advised or sub‑advised by Dimensional and that Dimensional disclaims beneficial ownership while reporting sole voting power over 1,447,712 shares and sole dispositive power over 1,474,089.
The Schedule 13G indicates the position is held in the ordinary course of business and not to influence control of the issuer. The filing was signed by Dimensional's Global Chief Compliance Officer on 10/09/2025.
Castle Biosciences (CSTL) director and CEO Derek J. Maetzold reported a sale of 1,339 shares of common stock on 10/02/2025 at a weighted-average price of $22.58 per share under a pre-existing Rule 10b5-1 trading plan adopted on 5/08/2025. After the transaction, the filing shows 64,327 shares held directly by the reporting person and multiple indirect holdings across family and trust vehicles, including trusts named in the filing.
The sale was executed in multiple trades at prices ranging from $22.31 to $23.14, and the filer said they will provide detailed trade-by-trade information upon request. The Form 4 is a routine Section 16 disclosure showing an insider sale conducted under an affirmative-defense plan rather than an ad-hoc transaction.
Derek J. Maetzold, President & Chief Executive Officer and a director of Castle Biosciences, sold 1,339 shares of Castle Biosciences common stock on 09/17/2025 under a preexisting Rule 10b5-1 plan at a weighted-average price of $21.971 per share. After the sale, the filing reports Mr. Maetzold directly or indirectly beneficially owns multiple blocks of shares held in various trusts, with specific reported holdings including 65,666 shares directly and several trust holdings (for example, 52,923; 44,986; multiple 3,615–3,618 blocks; and larger grantor retained annuity trusts of 85,959; 18,718; and 44,323).
The Form 4 explains the sale was effected through multiple trades at prices ranging from $21.860 to $22.085 and that the transactions were executed pursuant to a 10b5-1 plan adopted May 8, 2025. The form is signed by an attorney-in-fact on behalf of the reporting person.